Artivion saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an increase from 80 to 93.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating at the beginning of a new climb.
Artivion has risen more than 5% past a 29.73 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Top and bottom line growth moved higher last quarter. Earnings were up 243%, compared to 0% in the prior report. Revenue increased from 2% to 15%.
Artivion earns the No. 8 rank among its peers in the Medical-Products industry group. Insulet, ResMed and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
